Generated by AI
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform. The company’s current work centers on gene-silencing candidates designed to help immune cells better recognize and attack tumor cells, with a primary emphasis on cancer research and treatment applications. Its lead programs include PH-762, which targets PD-1 expression in ongoing clinical studies, and PH-894, which is being evaluated in preclinical research for selective BRD4 silencing. Phio Pharmaceuticals Corp. operates in the biotechnology sector and plays a role in advancing RNAi-based approaches for oncology, particularly in areas such as skin cancers and other solid tumors.
Website411 Swedeland Road
King of Prussia, PA, 19406
United States
The latest articles about PHIO.
Summary of Aug 19's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Summary of Feb 10's posts. Generated by AI.
Summary of Feb 15's posts. Generated by AI.
Investors talking about PHIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.